# Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users

> **NCT00270257** · PHASE3 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 1251 (actual)

## Conditions studied

- HIV Infections
- Opioid-Related Disorders

## Interventions

- **DRUG:** Buprenorphine/Naloxone

## Key facts

- **NCT ID:** NCT00270257
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-05
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 1251 (ACTUAL)
- **Why stopped:** DSMB halted the study due to futility as a result of lower than anticipated HIV incidence rates
- **Last updated:** 2021-11-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00270257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00270257, "Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00270257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*